ABSTRACT: Methicillin-resistant Staphylococcus aureus (MRSA) reinfection following revision surgery remains a major orthopaedic problem. Toward the development of immunotherapy with anti-glucosaminidase monoclonal antibodies (anti-Gmd), we aimed to: (i) develop a murine 1-stage exchange model of bioluminescent MRSA (USA300LAC::lux) contaminated femoral implants; and (ii) utilize this model to demonstrate the synergistic effects of combination vancomycin and anti-Gmd therapy on reinfection and bone healing. Following an infection surgery, the original plate and two screws were removed on day 7, and exchanged with sterile implants. Mice were randomized to five groups: (i) no infection control; (ii) infected placebo; (iii) anti-Gmd; (iv) vancomycin; and (v) combination therapy. Bioluminescent imaging (BLI) was performed on days 0, 1, 3, 5, 7, 8, 10, 12, and 14. Mice were euthanized on day 14 (day 7 post-revision), and efficacy was assessed via colony forming units (CFU) on explanted hardware, micro-CT, and histology. As monotherapies, anti-Gmd inhibited Staphylococcus abscess communities, and vancomycin reduced CFU on the implants. However, only combination therapy prevented increased BLI post-revision surgery, with a significant 6.5-fold reduction on day 10 (p < 0.05 vs. placebo), and achieved sterile implant levels by day 12. Synergistic effects were also apparent from reduced osteolysis and increased new bone formation around the screws only observed following combination therapy. Taken together, we find that: (i) this murine femoral plate 1-stage revision model can efficiently evaluate therapies to prevent reinfection; and (ii) immunotherapy plays a distinct role from antibiotics to reduce reinfection following revision surgery, such that synergy to achieve osseointegration is possible. ß
Orthopaedic implants are highly susceptible to bacterial infection due to the compromised host environment from surgery, and the nidus provided by the foreign body. 1 Recent reports on the risk of infection following internal fixation in the civilian population have found that they range from 1.6 to 4.2% for closed fractures and 8.0 to 14.7% for open fractures. 2, 3 Despite being an elective surgery, which allows for antibiotic prophylaxis, the incidence of periprosthetic joint infection (PJI) has been shown to range from 0.6 to 3.0%. 4, 5 Moreover, $13% of these patients become septic and die from multiorgan failure. [5] [6] [7] These orthopaedic implant infections are also very costly, and range from $25,000-114,000 per patient. [8] [9] [10] [11] [12] Importantly, Staphylococcus aureus is responsible for approximately 60% of these cases, of which over half are methicillin resistant S. aureus (MRSA) strains. 4 The prevalence of MRSA in orthopaedic implant infections is due to a multitude of mechanisms these commensal pathogens have developed to promote immune evasion, including: (i) biofilm formation on the implant 13 and necrotic bone, 14, 15 (ii) generation of Staphylococcus abscess communities (SACs) in soft tissues and bone marrow, 16, 17 and the ability to colonize the osteocytic-canalicular network of live cortical bone. 18, 19 Thus, reinfection rates from MRSA are very high (15-40%), and often require an implantexchange surgery to remedy the problem. [20] [21] [22] [23] [24] While an obvious solution to the problems of S. aureus infection is immunization, unfortunately, all efforts to develop an effective vaccine to date have failed for numerous reasons. 25, 26 This lack of success has generated a major controversy in the field regarding the role of humoral immunity during S. aureus infections, and doubt that immunotherapy is a scientifically valid approach to treat life-threatening surgical site infections. 25, [27] [28] [29] [30] While this controversy has raged for some time, it has recently been amplified by patient deaths in a large phase 2 clinical trial of the V710 vaccine, 31, 32 and questions as to how the FDAregulated pre-clinical development program reached the wrong conclusions regarding V710's safety and efficacy for the intended clinical indication. 33, 34 As there is now broad agreement that a major contributing factor is the absence of an in vivo model with face and construct validity of surgical site infections, 35 we aimed to develop the first small animal model of a 1-stage revision surgery for MRSA implant-associated osteomyelitis that incorporates salient clinical standards of care (debridement surgery and vancomycin therapy), and specific outcome measures to quantify in vivo planktonic growth (longitudinal bioluminescent imaging, BLI), biofilm bacterial on the implants (colony forming units, CFUs), osteolysis and osseointegration (micro-CT), and Staphylococcus abscess communities (SAC, Gram stained histology). 13, 17, 36 From a molecular mechanism of action standpoint, an ideal passive immunotherapy would comprise a dual-acting monoclonal antibody (mAb) with both direct antimicrobial effects through inhibition of a critical S. aureus target, and also have immunomodulatory effects to enhance the host response and bacterial clearance. For these reasons, we have focused our efforts on the glucosaminidase (Gmd) subunit of autolysin (Atl), 7, 17, 37 which several groups have identified as an immunodominant antigen. 38, 39 Functionally, Atl has been shown to be essential for cell wall biosynthesis and degradation during binary fission. [40] [41] [42] Atl has also been shown to function as an adhesin, 43 a biofilm enzyme, 44 a mediator of host cellular internalization/immune evasion. 45 Interestingly, S. aureus amidase (Amd), the other subunit of Atl, has been identified as a molecular target of vancomycin, 46 which is the standard of care treatment for MRSA. Thus, combination anti-Gmd and vancomycin therapy has synergistic potential. 39 Thus, we utilized our novel murine 1-stage revision model of MRSA implant-associated osteomyelitis to test the hypothesis that antibiotic and immunotherapy have unique molecular targets and mechanism of action, such that synergistic effects are observed with combination vancomycin and anti-Gmd therapy.
MATERIALS AND METHODS

Surgery and In Vivo Procedure
All animal experiments were performed on IACUC approved protocols. The 1-stage exchange model was designed by modifying a plated femoral osteotomy model, 6 and the overall experimental design is illustrated in Figure 1 . Briefly, female BALB/cJ mice were purchased from Jackson Research Labs (Bar Harbor, ME) at 10 weeks of age, and acclimated for one week prior to surgery. We utilized standard microisolator caging with free access to chow and water, within a vivarium that maintains 12 h light/dark cycle, and less than six mice were housed per cage Prior to surgery, the mice were sedated and anesthetized with xylazine (12 mg/kg) and ketamine (130 mg/kg) injected intraperitoneally. The right femur was exposed by a direct lateral approach, and a 4-hole titanium plate was fixed to the femur with two titanium screws inserted into the innermost screw holes of the plate (RISystem; Davos, Switzerland). To establish infection, the distal screw was incubated in an overnight culture with a bioluminescent MRSA strain (USA300LAC::lux 47 ) and then air-dried for 20 min prior to insertion. This MRSA exposure coats the screw with $10 5 CFU, and induces infection in 100% of untreated mice. Alternatively, a sterile screw was directly inserted as an uninfected-negative control. All implants were removed 7 days after primary surgery, followed by thorough irrigation Figure 1 . Schematic overview of the murine femoral plate 1-stage revision model. The initial surgery to establish the implant-associated bone infection involves implantation of a 4-hole titanium plate into the intact femur of a 10-week-old mouse with two titanium screws inserted into the innermost screw holes (RISystem; Davos, Switzerland). Prior to implantation, the distal screw is submerged in an overnight culture of a bioluminescent MRSA strain (USA300LAC::lux), and then air-dried for 20 min. This MRSA exposure coats the screw with $10 5 CFU, and induces infection in 100% of untreated mice. To confirm equivocal MRSA infection in the mice prior to treatment, in vivo BLI is performed on days 0, 1, 3, 5, and 7, and the explanted plate and screws are processed for CFU analysis. Immediately following removal of all implants on day 7, the revision surgery commences with reaming of the screw holes in the bone, and thorough debridement and irrigation with sterile PBS. Then a new sterile plate is fixed with two new sterile screws that are inserted into the outermost screw holes of the plate. Relapse of the MRSA infection is monitored via in vivo BLI on days 8, 10, 12, and 14. Following euthanasia on day 14, the explanted plate and screws are processed for CFU analysis, and the infected femur is harvested for mCT and histology to assess osteolysis, osteogenesis, and abscess formation. For quality control, plain X-rays are obtained on days 0, 3, 7, 10, and 14 to confirm proper implant alignment. In rare cases, mice were excluded from the study due to obvious malalignment, implant migration, or fracture (see Supplemental Figs. S1 and S2). For treatment studies, passive immunization was given on day 6 (the day before revision surgery), and antibiotic therapy commences at the time of revision surgery.
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with sterile PBS and debridement. Afterward, the femur was fixed again with a new sterile plate, and two sterile screws inserted into the outermost unused screw holes, and the mice were euthanized on day 7 post-revision (14 days after initial infection). For quality control, plain X-rays are obtained on days 0, 3, 7, 10, and 14 to confirm proper implant alignment. In rare cases (four out of 49; 8.2%), mice were excluded from the study due to obvious malalignment, implant migration, or fracture (see Supplemental Figs. S1 and S2).
Five treatment groups were evaluated: Group (1) Sterile implant (negative control; n ¼ 5); Group (2) Infected placebo (40 mg/kg irrelevant Ig control antibody (mouse anti-T2 mycotoxin purchased from Southern Biotech, Birmingham, AL)) injected intraperitoneally on day 6 post-infection; n ¼ 10); Group (3) Anti-Gmd monotherapy (40 mg/kg 1C11 IgG2a 17 injected intraperitoneally on day 6 post-infection; n ¼ 10); Group (4) Vancomycin monotherapy (110 mg/kg/day subcutaneously, 48 from day 7 until sacrifice; n ¼ 10); and Group (5) Combination anti-Gmd and vancomycin therapy (n ¼ 10). In vivo bacterial infection was monitored by longitudinal BLI on days 0, 3, 7, 10, and 14 as previously described. 17 Ex Vivo Analyses Mice were euthanized on day 14 post-primary surgery (day 7 post-revision surgery), and the implants and femurs were harvested for ex vivo analyses. The bacterial burden on the implants was determined for both the primary and revision fixation hardware via CFU assay following sonication, as previously described. 13 Osteolysis and new bone formation around the originally contaminated screw hole (3rd screw hole) were assessed by ex vivo micro-CT as described in Supplemental Figure S3 . Femurs were processed for demineralized histology, and 5 mm sections were stained with Brown and Brenn to identify Gram þ bacteria and SACs, or alcian blue hematoxylin/orange G (ABH/OG) to assess new bone formation, as previously described. 17 Statistical Analysis Data are presented as mean AE one standard deviation. Imaging studies (BLI and micro-CT) were assessed by heteroscedastic ANOVA with Holm adjustment, and CFU assays were assessed by Kruskal-Wallis with Dunn's multiple comparison test, for which p < 0.05 was considered statistically significant.
RESULTS
As chronic osteomyelitis following implant surgery is commonly defined as an infection that persists beyond 3-weeks, we aimed to recapitulate this in our initial 1-stage revision model, in which mice received a MRSA contaminated femoral plate that was revised on day 7, and received no additional treatment out to 28 days. Unfortunately, this lengthy delay in treatment proved intolerable, as we observed various catastrophic failures in the majority of the infected mice that included: Complete femur fracture, and massive segmental defects with loss of all implants (Supplemental Fig. S1 ). Given the serious animal welfare concerns, we arrived at the current model (Fig. 1) , which provided adequate fixation out to day 14 post-infection in all untreated mice that we studied.
To assess the efficacy of anti-Gmd and vancomycin therapy, alone and in combination in the murine femoral plate 1-stage revision model describe in Figure 1 , mice were randomly assigned into the five Groups, and longitudinal BLI post-op was performed to ensure similar infections in Groups 1-4, and the absence of infection in Group 5 ( Fig. 2A and B) . Consistent with prior studies, 17, 36, 48 we observed a peak BLI in the infected mice on day 3, which corresponds to the transition from planktonic to biofilm bacteria, 13 and no BLI signal in the sterile implant Group. To further confirm similar levels of infection in Groups 1-4, and its absence in Group 5, we performed CFU assays on the explanted screws and plates obtained during revision surgery on day 7. The results demonstrated similar levels of MRSA colonization of the hardware in Groups 1-4, and sterility in Group 5 (Fig. 2C) . As no significant differences were observed between any of the infection Groups, further randomization to the treatments was unwarranted, and all mice remained in their originally assigned Group.
To assess drug effects on in vivo MRSA growth following debridement and revision surgery, we performed longitudinal BLI out to day 14 post-primary surgery (Fig. 3) . The results demonstrated the predicted relapse of the infection in the Placebo Group, 49 which display a BLI peak on day 10 (day-3 postrevision), and no BLI signal in the Sterile Implant Group. However, the three drug treatment Groups displayed different BLI behaviors. The anti-Gmd monotherapy Group displayed a trend of reduced BLI after day 8 (day-1 post-revision). Although the vancomycin monotherapy Group displayed a clearly reduced BLI over the treatment phase, there was still a BLI peak on day 10. In contrast, synergistic effects in the combination Group were evidenced by: (i) the absence of any increase in BLI post-revision surgery; (ii) a significant decrease in BLI on day 10 (p < 0.05 vs. Placebo); and (iii) the absence of detectable BLI after day 10.
To assess drug effects on MRSA colonization of the revision implants, CFU assays were performed on the explanted screws and plates (Fig. 4) . The results demonstrated that all sterile implants had no CFU, and antiGmd monotherapy had no effect on CFUs per implant. In contrast, both vancomycin monotherapy and combination therapy had a similar significant reduction in CFUs on the plate and screws (p < 0.05 vs. Placebo). As these findings are distinct from the BLI outcomes, the results also demonstrate that MRSA colonization of implants in vivo occurs via mechanisms distinct from planktonic growth, which is known to be inhibited by anti-Gmd antibodies. 17 To assess drug effects on osteolysis and new bone formation following 1-stage revision surgery, the implanted femurs were harvested on day 14 postprimary surgery for ex vivo micro-CT. Interestingly, the results showed that only combination therapy significantly decreased the osteolysis volume (Fig. 5) . In order to assess new cortical bone around the infected screw hole, and within the reamed medullary canal space of the infected screw hole, we quantified these ROIs independently (Fig. 6) . The results demonstrated that . Decreased bacterial burden on revision implants is only due to antibiotic therapy. Femurs from the mice described in Figure 3 were harvested on day 14 post-primary surgery, the implants were removed and processed for CFU assays. The results are graphed as CFUs per implant with mean AE SD for each Group. Note that all sterile implants had no CFU, and 1C11 monotherapy had no effect on CFUs per implant. In contrast, both VCM and Combo treatments had a similar significant reduction in CFUs on the plate and screws ( Ã p < 0.05 vs. Placebo by Kruskal-Wallis with Dunn's multiple comparison test).
IMMUNOTHERAPY SYNERGIZES WITH DEBRIDEMENT AND ANTIBIOTIC THERAPY very little new cortical bone forms around the femoral screw holes, even for the sterile implant controls (Fig. 6V) . In contrast, medullary new bone formation was robust in the sterile implant Group (Fig. 6T) . Moreover, combination therapy significantly increased the new bone formation in the medullary canal versus placebo, anti-Gmd, and vancomycin therapies (Fig. 6X) .
To confirm the significant and synergistic effects of combination therapy, and provide insights on the distinct mechanisms of action of anti-Gmd and vancomycin therapy responsible for this synergy, we performed histology on the infected femurs (Fig. 7) . The results from the Brown and Brenn-stained histology were distinct for all four treated infection groups. Femurs from Placebo treated mice contain copious amounts of Gram þ bacteria within the soft tissue and bone adjacent to the screw hole (Fig. 7A) . While Gram þ bacteria were present in femurs from antiGmd monotherapy treated mice, sterile abscesses (SACs devoid of Gram þ bacteria) were also prominently featured (Fig. 7B) . Interestingly, SACs containing Gram þ bacteria were prevalent in femurs from vancomycin monotherapy treated mice (Fig. 7C) . Remarkably, no SACs were found in tissues from mice that received combination therapy, and Gram þ bacteria were only identified in necrotic cortical bone immediately adjacent to some of the screw holes (Fig. 7D) . The results from the ABH/OG stained histology confirmed the micro-CT findings, in that new bone formation on and within femurs from Placebo and anti-Gmd monotherapy treated mice did not occur ( Fig. 7E and F) , and sporadic new bone was evident on and within femurs from mice treated with vancomycin monotherapy (Fig. 7G) . However, histological assessment of new bone formation on and within femurs from mice that received the combination therapy suggest that the micro-CT findings underestimated the significant drug effects (Fig. 7H) . Most specifically, we observed evidence of bridging cortical bone on both cortices, and osseointegration (bone formation around the new screws), which cannot occur in the setting of osteomyelitis in our murine models.
13,36,48
DISCUSSION
Implant-associated osteomyelitis, primarily from S. aureus infection, is a bane of orthopaedic surgery. Given the tremendous impact of these infections on patients and healthcare systems, a therapeutic solution to this problem has been a top priority for decades. One approach that has held great promise since its advent in the 1980s is immunotherapy, which has been realized in FDAapproved treatments against toxins (i.e., botulism, diphtheria, tetanus) and viral infections (i.e., cytomegalovirus, hepatitis, measles, rabies, vaccinia). Unfortunately, all efforts to develop a similar passive immunization for S. aureus have failed, and enthusiasm for this approach has waned in the 21st century. 25, 26 Of note is that these disappointments have been paralleled by a paucity of success in immunotherapies for cancer, until recently. Remarkably, it was a paradigm change in molecular targeting, from adjuvants that stimulate the immune system in general (i.e., interleukins and interferons), to blocking "checkpoint inhibitors" of specific anti-tumor immunity, which paved the way toward antibody-based therapies targeting cytotoxic T-lymphocyte antigen-4 (ipilimumab, tremelimumab), programmed cell death-1 (nivolumab, pembrolizumab), and programmed cell death ligand-1 (atezolizumab). Thus, a central question is, could a similar paradigm change in molecular targeting of S. aureus antigens lead to an effective treatment for the most common form of osteomyelitis? Based on this rationale, we shifted our attention from traditional antigens including secreted toxins (a-hemolysin, Panton-Valentine leukocidin), iron-scavenging proteins (IsdA, IsdB, IsdH), capsular polysaccharides, and cell-wall adhesins (ClfA, FnbpA), to focus on anti-Gmd. 7 ,17,37 Figure 5 . Synergistic effects of combination antibiotic and immunotherapy on osteolysis following 1-stage revision surgery as assess by mCT. The implanted femurs described in Figure 3 were harvested on day 14 post-primary surgery, and processed for volumetric mCT as described in Supplemental Figure S3 . A 3D renderings of representative femurs from each Group are shown to illustrate the extensive osteolysis (blue arrowheads) adjacent to the contaminated distal screw, and at the ends of the plate, in femurs from Placebo and 1C11 treated mice. This osteolysis appeared to be reduced by VCM, and was remarkably decreased in the Combo Group. No osteolysis was observed in the Sterile Implant Group, while new bone formation (yellow arrowhead) in the vacated screw hole was apparent in these femurs. The normalized osteolysis volume for each femur is presented as individual femurs with the mean for each Group. Note that the Combo Group displayed a significant reduction in osteolysis ( Ã p < 0.05 vs. Placebo by heteroscedastic ANOVA model with Holm adjustment).
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Another established weakness in the field of therapies for surgical-site infections is the absence of an animal model with face and construct validity. 35 Thus, in addition to evaluating anti-Gmd therapy, we also aimed to develop the first small animal model of a 1-stage revision surgery for MRSA implant-associated osteomyelitis that incorporates salient clinical standards of care. While investigators have recently succeeded in developing murine models that closely resemble the clinical situations of periprosthetic joint infection, and fracture fixation, our bias in small animal models favors minimal within group variation and rigorous outcome measures for robust statistical analyses. Thus, although a limitation of our model is the absence of a clinically relevant injury, we find the femoral plate model described in Figure 1 to be reproducible with a <5% failure rate due to malalignment, implant migration or fracture (Supplemental Figs. S1 and S2) . Moreover, the inclusion of longitudinal BLI over the first week post-op allows for quality control of the infection ( Fig. 2A and  B) , and subsequent normalization or randomization of study animals prior to treatment, which proved not to be necessary in this study. We also performed CFU assessments on the primary plates and screws as a quality control to verify similar levels of infection in all treatment groups (Fig. 2C) . Interestingly, the results showed uniform colonization of the distal screw and plate ($5 Â 10 5 CFU per implant), which were contaminated with the MRSA culture via direct contact at the time of surgery. In contrast, the level of proximal screw colonization was markedly decreased and highly variable (ranging from 0 to 10 5 CFU per implant). As MRSA colonization of the proximal screw requires in Figure 6 . Synergistic effects of combination antibiotic and immunotherapy on new bone formation in the infected screw hole following 1-stage revision surgery as assess by mCT. The mCT data described in Figure 5 was also analyzed for new bone formation within the posterior-cortical screw hole, and the medullary canal of the 3rd screw hole, individually, as described in Supplemental Figure S3 . Representative 3D renderings of the posterior-cortical screw hole (A-E), new bone within this ROI (F-J), and sagittal view of the 3rd screw hole with new bone within this ROI (P-T) are shown with statistical analyses for both ROIs (U-X; Ã p < 0.05 vs. Combo by ANOVA).
IMMUNOTHERAPY SYNERGIZES WITH DEBRIDEMENT AND ANTIBIOTIC THERAPY vivo migration of the bacteria from the distal screw hole, this model may also be useful to study this aspect of implant-associated osteomyelitis in the future.
As any immunotherapy for osteomyelitis would have to be given as an adjuvant with standard of care antibiotics, our goal for MRSA is to develop a passive immunization that is synergistic with vancomycin. 46 To this end, here we report the first in vivo evidence that anti-Gmd immunotherapy, which is designed to inhibit bacterial dissemination and facilitate clearance via inhibition of binary fission and opsonophagocytosis of megaclusters, 17, 37 synergizes with a cytostatic antibiotic. Importantly, our results also demonstrated unique outcomes in the monotherapy groups, which substantiate the distinct mechanisms of actions, and account for the synergistic efficacy on infection and the bone. Specifically, the delayed effects of anti-Gmd, as determined by BLI (Fig. 3) , are explained by the fact that the bacteria must undergo replication prior to megacluster formation, while vancomycin immediately decreases BLI via direct cytostatic effects. By combining these antimicrobial activities, no increase in BLI is observed following revision surgery largely due to bacteria stasis, and the infection is eradicated via immunomodulation of the host response. While our conclusions on the synergistic effects observed on osteolysis and new bone formation are more speculative, we reason that anti-Gmd inhibition of bacterial dissemination and rapid clearance would reduce the local inflammatory response that drives bone loss and inhibits osseous integration, while vancomycin decreases colonization of the revision implants.
Although our findings support further development of anti-Gmd immunotherapy as an adjuvant to vancomycin treatment of implant-associated osteomyelitis, there are two notable limitations of our study. The first is that this is an initial proof of concept study that needs to be confirmed in other in vivo models, including large animal models that better reflect the clinical situation in terms of size and chronicity of infection. 50 Secondly, we describe effects of a murine monoclonal antibody in mouse model, and it remains to be seen if a human anti-Gmd antibody could have similar effects in animals and patients. Thus, additional research is needed to further assess this immunotherapy approach to prevent and treat S. aureus bone infections.
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